Literature DB >> 3570485

[Prevention of gram-negative and gram-positive infections using 3 intravenous immunoglobulin preparations and therapy of experimental polymicrobial burn infection using intravenous Pseudomonas immunoglobulin G and ciprofloxacin in an animal model].

M S Collins, R F Hector, R E Roby, A A Edwards, D K Ladehoff, J H Dorsey.   

Abstract

Three immunoglobulin preparations for intravenous infusion were compared in vivo to determine their relative protective capacity against several gram-negative and gram-positive pathogens. Polyglobin N is a conventional IgG concentrate. Psomaglobin N is identical in formulation to Polyglobin N but is prepared from the plasma of donors who have naturally high levels of antibody to lipopolysaccharide antigens of Pseudomonas aeruginosa. IgGMA is a conventional IgG concentrate containing 12% IgG and 16% IgA. In a murine model of burn wound sepsis the three IgG preparations were similarly protective against three or ten strains of P. aeruginosa. Psomaglobin N and Polyglobin N were significantly (p less than or equal to 0.015) more protective than IgG-MA against six of ten and three of ten strains of P. aeruginosa, respectively. In a murine model of Streptococcus pneumoniae type 3 pneumonia, the three Ig preparations were similarly protective. IgG-MA was significantly more protective (p less than or equal to 0.025) than Psomaglobin N and Polyglobin N against Salmonella typhimurium in murine peritonitis. However, the mean protective dose (PD50) of the two later preparations was less than or equal to 20 mg/kg body weight. In models of peritonitis both Psomaglobin N and Polyglobin N were more protective than IgGMA (p less than or equal to 0.004) against Haemophilus influenzae b, Klebsiella pneumoniae, Serratia marcescens 06:H3 and group B Streptococcus types 1b and 1c. Psomaglobin N and ciprofloxacin were employed to treat established polymicrobial murine burn wound sepsis resulting from contamination of the burn site with mixtures of P. aeruginosa and Staphylococcus aureus. Psomaglobin N or albumin was given once 16 h after challenge.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3570485     DOI: 10.1007/bf01646125

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  27 in total

Review 1.  The gamma globulins. 3. The antibody deficiency syndromes.

Authors:  F S Rosen; C A Janeway
Journal:  N Engl J Med       Date:  1966-09-29       Impact factor: 91.245

2.  Undegraded human immunoglobulin for intravenous use.

Authors:  W Stephan
Journal:  Vox Sang       Date:  1975       Impact factor: 2.144

3.  Binding of protein A to some human gamma-globulins used intravenously.

Authors:  M Ceska
Journal:  Vox Sang       Date:  1981       Impact factor: 2.144

4.  Comparative in vivo activity between intravenous immune globulin prepared by reduction and alkylation or by low pH.

Authors:  M S Collins; J H Dorsey
Journal:  J Infect Dis       Date:  1985-06       Impact factor: 5.226

5.  Evaluation of gamma globulin for prophylaxis against burn sepsis.

Authors:  H H Stone; C D Graber; J D Martin; L Kolb
Journal:  Surgery       Date:  1965-11       Impact factor: 3.982

6.  Burn wound infection.

Authors:  W F McManus; C W Goodwin; A D Mason; B A Pruitt
Journal:  J Trauma       Date:  1981-09

7.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

8.  In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

Authors:  G M Eliopoulos; A Gardella; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

9.  Exotoxin production by clinical isolates of pseudomonas aeruginosa.

Authors:  M Pollack; N S Taylor; L T Callahan
Journal:  Infect Immun       Date:  1977-03       Impact factor: 3.441

10.  Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans.

Authors:  M Pollack
Journal:  J Infect Dis       Date:  1983-06       Impact factor: 5.226

View more
  5 in total

1.  Re: Prophylaxis of gram-negative and gram-positive infections in rodents with three intravenous immunoglobulins and therapy of experimental polymicrobial burn wound sepsis with pseudomonas immunoglobulin and ciprofloxacin.

Authors:  W Stephan; H Dichtelmüller
Journal:  Infection       Date:  1987 Nov-Dec       Impact factor: 3.553

2.  [Pseudomonas immunoglobulin prophylaxis in patients with burn injuries].

Authors:  R Stuttmann; V Petrovici; M Hartert
Journal:  Infection       Date:  1987       Impact factor: 3.553

3.  Effect of polyclonal immunoglobulins on neutrophil phagocytic capacity and reactive oxygen production in patients with gram-negative septicemia.

Authors:  C Wenisch; B Parschalk; S Patruta; R Brustbauer; W Graninger
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

4.  [Prevention using a Pseudomonas immunoglobulin in burn patients].

Authors:  R Stuttmann; V Petrovici; M Hartert
Journal:  Infection       Date:  1987 Jan-Feb       Impact factor: 3.553

5.  Supplemental immunoglobulin (ivIgG) treatment in 163 patients with sepsis and septic shock--an observational study as a prerequisite for placebo-controlled clinical trials.

Authors:  G Pilz; S Kääb; G Neeser; I Class; U Schweigart; A Brähler; O Bujdoso; R Neumann; K Werdan
Journal:  Infection       Date:  1991 Jul-Aug       Impact factor: 3.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.